SlideShare a Scribd company logo
1 of 2
Download to read offline
TIME IS OF THE ESSENCE IN DRUG DEVELOPMENT.
CONTACT THE QPS BUSINESS DEVELOPMENT TEAM TODAY!
CALL +1 512 350 2827 EMAIL infobd@qps.com
Biomarkers &
Translational
Medicine
A flexible approach to
AT QPS, TRANSLATIONAL MEDICINE BRINGS
TOGETHER LEADING-EDGE TECHNOLOGIES AND
pharmaceutical research and development experience
to create a business service unit that works efficiently to
advance your drug development program.
Fargo, ND, USA
Dermal and Transdermal
Research Laboratory (DTRL)
Groningen and Leeuwarden,
The Netherlands
Bioanalysis (BA)
Clinical Research Services (CRS)
Translational Medicine (TLM)
Suzhou and Shanghai,
China
Bioanalysis (BA)
Clinical Research Services (CRS)
Miami, FL, USA
Clinical Research
Services (CRS)
Hyderabad, India
Bioanalysis (BA)
Clinical Research
Services (CRS)
Taipei, Taiwan
Bioanalysis (BA)
Clinical Research Services (CRS)
Toxicology (TOX)
Newark, DE, USA
Bioanalysis (BA)
Clinical Research Services (CRS)
DMPK
Translational Medicine (TLM)
Global Headquarters for
QPS Holdings LLC
Graz, Austria
Clinical Research Services (CRS)
DMPK
Histology Services
Neuropharmacology
Rare Disease
Rodent Biobank
Springfield, MO, USA
Clinical Research
Services (CRS)
Translational Medicine Overview
Projects in translational medicine include qualification/
validation of commercially available kits, method
transfer of assays originated from the Sponsor’s lab, or
a collaborative effort between the QPS team and the
Sponsor’s lab for custom assays. We also develop assays
independently without help from the Sponsor. In addition
to immunoassays for PK and immunogenicity assessment,
QPS develops cell-based assays for neutralizing antibody
activity and biomarker evaluation in support of your drug
development programs.
Validation & Qualification
We work diligently with clients to determine
best practices for conducting biomarker or other
pharmacodynamic studies to support both preclinical
studies and clinical trials. As pharmacodynamics assays
are often for explorative use only, we have adopted a “fit-
for purpose” to qualify and validate assays. QPS can plan
a “fit-for-purpose” method qualification or validation that
identifies the key tests needed to ensure the suitability of
an assay method on an individual basis.
We can provide a shorter method qualification, usually
performed with a vendor-qualified assay kit. A qualification
typically includes 3 or more precision and accuracy runs
and matrix testing. In this case, assay specifications
including more extensive validation tests are provided
by the assay vendor. As a “fit-for-purpose” qualification,
additional tests may be added based on the nature of the
assay and specific study considerations. In some cases, an
inter-laboratory cross validation may be performed for data
comparison, using 20-30 samples provided by the sponsor.
In a “fit-for-purpose” method validation, the individual
biomarker characteristics and the study specifics are used
to determine which of these tests are appropriate. Some
tests may be eliminated on an individual basis if they are
not applicable to the particular biomarker, not useful for a
specific type of assay (e.g. activity assay) or if they are not
relevant to the clinical or pre-clinical study our method is
supporting. Additional tests may be added given the same
considerations.
A full method validation is typically described in a sponsor-
approved validation protocol and includes at least six assay
runs to determine both inter- and intra-batch precision
and accuracy, dilution linearity (hook effect tests), matrix
selectivity, matrix effect (n ≥ 6) and necessary stability tests
including benchtop (ambient temperature), freeze-thaw
and long-term storage.
QPS is a Global CRO with locations around the world
WWW.QPS.COM

More Related Content

What's hot

Virtual Screening and Hit Prioritization
Virtual Screening and Hit PrioritizationVirtual Screening and Hit Prioritization
Virtual Screening and Hit Prioritization
Puneet Kacker
 
Introducing VSClinical: Streamlining ACMG Variant Interpretation Guidelines
Introducing VSClinical: Streamlining ACMG Variant Interpretation GuidelinesIntroducing VSClinical: Streamlining ACMG Variant Interpretation Guidelines
Introducing VSClinical: Streamlining ACMG Variant Interpretation Guidelines
Golden Helix
 

What's hot (18)

Virtual Screening and Hit Prioritization
Virtual Screening and Hit PrioritizationVirtual Screening and Hit Prioritization
Virtual Screening and Hit Prioritization
 
ABT 609 PPT
ABT 609 PPTABT 609 PPT
ABT 609 PPT
 
MDC Connects Series 2021 | A Guide to Complex Medicines: Overcoming the Chall...
MDC Connects Series 2021 | A Guide to Complex Medicines: Overcoming the Chall...MDC Connects Series 2021 | A Guide to Complex Medicines: Overcoming the Chall...
MDC Connects Series 2021 | A Guide to Complex Medicines: Overcoming the Chall...
 
Rmc phenotypic screening
Rmc phenotypic screeningRmc phenotypic screening
Rmc phenotypic screening
 
RAC US Exam Questions
RAC US Exam QuestionsRAC US Exam Questions
RAC US Exam Questions
 
Regulatory Affairs Certification Dumps
Regulatory Affairs Certification DumpsRegulatory Affairs Certification Dumps
Regulatory Affairs Certification Dumps
 
Anaquant-Protein quantitation by mass spectrometry
Anaquant-Protein quantitation by mass spectrometryAnaquant-Protein quantitation by mass spectrometry
Anaquant-Protein quantitation by mass spectrometry
 
RAC US Study Guide
RAC US Study GuideRAC US Study Guide
RAC US Study Guide
 
MDC Connects Series 2021 | A Guide to Complex Medicines: Developing the assay...
MDC Connects Series 2021 | A Guide to Complex Medicines: Developing the assay...MDC Connects Series 2021 | A Guide to Complex Medicines: Developing the assay...
MDC Connects Series 2021 | A Guide to Complex Medicines: Developing the assay...
 
Pathway to the clinic and beyond
Pathway to the clinic and beyondPathway to the clinic and beyond
Pathway to the clinic and beyond
 
MDC Connects Series 2021 | A Guide to Complex Medicines: Where are we now, wh...
MDC Connects Series 2021 | A Guide to Complex Medicines: Where are we now, wh...MDC Connects Series 2021 | A Guide to Complex Medicines: Where are we now, wh...
MDC Connects Series 2021 | A Guide to Complex Medicines: Where are we now, wh...
 
Krunal_CV
Krunal_CVKrunal_CV
Krunal_CV
 
Open PHACTS (Sept 2013) EBI Industry Programme
Open PHACTS (Sept 2013) EBI Industry ProgrammeOpen PHACTS (Sept 2013) EBI Industry Programme
Open PHACTS (Sept 2013) EBI Industry Programme
 
High-Content Analysis & Phenotypic Screening Conference 2016
High-Content Analysis & Phenotypic Screening Conference 2016High-Content Analysis & Phenotypic Screening Conference 2016
High-Content Analysis & Phenotypic Screening Conference 2016
 
UCB Domainex Combinatorial Domain Hunting MEK kinase
UCB Domainex Combinatorial Domain Hunting MEK kinaseUCB Domainex Combinatorial Domain Hunting MEK kinase
UCB Domainex Combinatorial Domain Hunting MEK kinase
 
Introducing VSClinical: Streamlining ACMG Variant Interpretation Guidelines
Introducing VSClinical: Streamlining ACMG Variant Interpretation GuidelinesIntroducing VSClinical: Streamlining ACMG Variant Interpretation Guidelines
Introducing VSClinical: Streamlining ACMG Variant Interpretation Guidelines
 
MDC Connects Series 2021 | A Guide to Complex Medicines: The Advantages of Go...
MDC Connects Series 2021 | A Guide to Complex Medicines: The Advantages of Go...MDC Connects Series 2021 | A Guide to Complex Medicines: The Advantages of Go...
MDC Connects Series 2021 | A Guide to Complex Medicines: The Advantages of Go...
 
Drug design
Drug design Drug design
Drug design
 

Similar to QPS Biomarkers & Translational Medicine

Presentation GOOD LABORATORY PRACTICES .pptx
Presentation GOOD LABORATORY PRACTICES .pptxPresentation GOOD LABORATORY PRACTICES .pptx
Presentation GOOD LABORATORY PRACTICES .pptx
NafeesaHanif1
 
Study Design to Support Reimbursement
Study Design to Support ReimbursementStudy Design to Support Reimbursement
Study Design to Support Reimbursement
Lyssa Friedman
 
Developing the Reimbursement Story 2016-03-10
Developing the Reimbursement Story 2016-03-10Developing the Reimbursement Story 2016-03-10
Developing the Reimbursement Story 2016-03-10
Lyssa Friedman
 

Similar to QPS Biomarkers & Translational Medicine (20)

What Is Care?
What Is Care?What Is Care?
What Is Care?
 
Good Laboratory Practices and Safety Assessments
Good Laboratory Practices and Safety AssessmentsGood Laboratory Practices and Safety Assessments
Good Laboratory Practices and Safety Assessments
 
Validation of POCT_Rajendra.pptx
Validation of POCT_Rajendra.pptxValidation of POCT_Rajendra.pptx
Validation of POCT_Rajendra.pptx
 
Validation of POCT_Rajendra.pptx
Validation of POCT_Rajendra.pptxValidation of POCT_Rajendra.pptx
Validation of POCT_Rajendra.pptx
 
Presentation GOOD LABORATORY PRACTICES .pptx
Presentation GOOD LABORATORY PRACTICES .pptxPresentation GOOD LABORATORY PRACTICES .pptx
Presentation GOOD LABORATORY PRACTICES .pptx
 
Technology Considerations to Enable the Risk-Based Monitoring Methodology
Technology Considerations to Enable the Risk-Based Monitoring MethodologyTechnology Considerations to Enable the Risk-Based Monitoring Methodology
Technology Considerations to Enable the Risk-Based Monitoring Methodology
 
40718
4071840718
40718
 
Clinical Research Organization Services | Contract Research Company - Pepgra
Clinical Research Organization Services | Contract Research Company - PepgraClinical Research Organization Services | Contract Research Company - Pepgra
Clinical Research Organization Services | Contract Research Company - Pepgra
 
Targos_Company_Brochure_lowres
Targos_Company_Brochure_lowresTargos_Company_Brochure_lowres
Targos_Company_Brochure_lowres
 
Targos_Company_Brochure_lowres
Targos_Company_Brochure_lowresTargos_Company_Brochure_lowres
Targos_Company_Brochure_lowres
 
Multiplex
MultiplexMultiplex
Multiplex
 
5-Scientific Approach to Validation.pptx
5-Scientific Approach to Validation.pptx5-Scientific Approach to Validation.pptx
5-Scientific Approach to Validation.pptx
 
Study Design to Support Reimbursement
Study Design to Support ReimbursementStudy Design to Support Reimbursement
Study Design to Support Reimbursement
 
Developing the Reimbursement Story 2016-03-10
Developing the Reimbursement Story 2016-03-10Developing the Reimbursement Story 2016-03-10
Developing the Reimbursement Story 2016-03-10
 
Defining a Central Monitoring Capability: Sharing the Experience of TransCele...
Defining a Central Monitoring Capability: Sharing the Experience of TransCele...Defining a Central Monitoring Capability: Sharing the Experience of TransCele...
Defining a Central Monitoring Capability: Sharing the Experience of TransCele...
 
Quality, Risk & Compliance: Risk Management for Sponsors, Site, and CROs
Quality, Risk & Compliance: Risk Management for Sponsors, Site, and CROsQuality, Risk & Compliance: Risk Management for Sponsors, Site, and CROs
Quality, Risk & Compliance: Risk Management for Sponsors, Site, and CROs
 
Significance of CAP accreditation
Significance of CAP accreditationSignificance of CAP accreditation
Significance of CAP accreditation
 
Audit monitoring and inspections cro perspectives
Audit monitoring and inspections cro perspectivesAudit monitoring and inspections cro perspectives
Audit monitoring and inspections cro perspectives
 
Presentation China And Usa July 2011
Presentation   China And Usa July 2011Presentation   China And Usa July 2011
Presentation China And Usa July 2011
 
Review on Bioanalytical Method Development in Human Plasma
Review on Bioanalytical Method Development in Human PlasmaReview on Bioanalytical Method Development in Human Plasma
Review on Bioanalytical Method Development in Human Plasma
 

More from QPS Holdings, LLC

Three Lessons to Help Accelerate Pharmaceutical Breakthroughs for CNS Disorders
Three Lessons to Help Accelerate Pharmaceutical Breakthroughs for CNS DisordersThree Lessons to Help Accelerate Pharmaceutical Breakthroughs for CNS Disorders
Three Lessons to Help Accelerate Pharmaceutical Breakthroughs for CNS Disorders
QPS Holdings, LLC
 

More from QPS Holdings, LLC (20)

Defining a Full Service ADME Data Package
Defining a Full Service ADME Data Package Defining a Full Service ADME Data Package
Defining a Full Service ADME Data Package
 
QPS DMPK
QPS DMPKQPS DMPK
QPS DMPK
 
QPS Neuropharmacology
QPS NeuropharmacologyQPS Neuropharmacology
QPS Neuropharmacology
 
QPS Bioanalysis General
QPS Bioanalysis General QPS Bioanalysis General
QPS Bioanalysis General
 
QPS CSF Sampling
QPS CSF SamplingQPS CSF Sampling
QPS CSF Sampling
 
QPS Immunogenicity
QPS ImmunogenicityQPS Immunogenicity
QPS Immunogenicity
 
QPS IND Enabling Preclinical Studies
QPS IND Enabling Preclinical StudiesQPS IND Enabling Preclinical Studies
QPS IND Enabling Preclinical Studies
 
QPS Negative Pressure Room
QPS Negative Pressure RoomQPS Negative Pressure Room
QPS Negative Pressure Room
 
QPS Regulated Bioanalysis of Antibody Drug Conjugates
QPS Regulated Bioanalysis of Antibody Drug ConjugatesQPS Regulated Bioanalysis of Antibody Drug Conjugates
QPS Regulated Bioanalysis of Antibody Drug Conjugates
 
QPS LC-MS MS of Small & Large Molecules
QPS LC-MS MS of Small & Large MoleculesQPS LC-MS MS of Small & Large Molecules
QPS LC-MS MS of Small & Large Molecules
 
QPS Gene Therapy Milestones
QPS Gene Therapy MilestonesQPS Gene Therapy Milestones
QPS Gene Therapy Milestones
 
QPS Bioanalysis Milestones
QPS Bioanalysis MilestonesQPS Bioanalysis Milestones
QPS Bioanalysis Milestones
 
Overcoming Pediatric Trial Challenges
Overcoming Pediatric Trial ChallengesOvercoming Pediatric Trial Challenges
Overcoming Pediatric Trial Challenges
 
Biosimilar Dug Development
Biosimilar Dug DevelopmentBiosimilar Dug Development
Biosimilar Dug Development
 
Three Lessons to Help Accelerate Pharmaceutical Breakthroughs for CNS Disorders
Three Lessons to Help Accelerate Pharmaceutical Breakthroughs for CNS DisordersThree Lessons to Help Accelerate Pharmaceutical Breakthroughs for CNS Disorders
Three Lessons to Help Accelerate Pharmaceutical Breakthroughs for CNS Disorders
 
RNAi Therapeutics
RNAi TherapeuticsRNAi Therapeutics
RNAi Therapeutics
 
Pharmacokinetic Studies in Patients
Pharmacokinetic Studies in PatientsPharmacokinetic Studies in Patients
Pharmacokinetic Studies in Patients
 
Seeking Drug Approval via the 505(b)(2) NDA Option
Seeking Drug Approval via the 505(b)(2) NDA OptionSeeking Drug Approval via the 505(b)(2) NDA Option
Seeking Drug Approval via the 505(b)(2) NDA Option
 
Transdermal Delivery Systems
Transdermal Delivery SystemsTransdermal Delivery Systems
Transdermal Delivery Systems
 
Selecting the Location of a Phase I Clinical Trial Site for EU Registration
Selecting the Location of a Phase I Clinical Trial Site for EU RegistrationSelecting the Location of a Phase I Clinical Trial Site for EU Registration
Selecting the Location of a Phase I Clinical Trial Site for EU Registration
 

Recently uploaded

Recently uploaded (20)

Hemodialysis: Chapter 2, Extracorporeal Blood Circuit - Dr.Gawad
Hemodialysis: Chapter 2, Extracorporeal Blood Circuit - Dr.GawadHemodialysis: Chapter 2, Extracorporeal Blood Circuit - Dr.Gawad
Hemodialysis: Chapter 2, Extracorporeal Blood Circuit - Dr.Gawad
 
Integrated Neuromuscular Inhibition Technique (INIT)
Integrated Neuromuscular Inhibition Technique (INIT)Integrated Neuromuscular Inhibition Technique (INIT)
Integrated Neuromuscular Inhibition Technique (INIT)
 
5CL-ADB powder supplier 5cl adb 5cladba 5cl raw materials vendor on sale now
5CL-ADB powder supplier 5cl adb 5cladba 5cl raw materials vendor on sale now5CL-ADB powder supplier 5cl adb 5cladba 5cl raw materials vendor on sale now
5CL-ADB powder supplier 5cl adb 5cladba 5cl raw materials vendor on sale now
 
DEVELOPMENT OF OCCLUSION IN PEDIATRIC DENTISTRY
DEVELOPMENT OF OCCLUSION IN PEDIATRIC DENTISTRYDEVELOPMENT OF OCCLUSION IN PEDIATRIC DENTISTRY
DEVELOPMENT OF OCCLUSION IN PEDIATRIC DENTISTRY
 
A thorough review of supernormal conduction.pptx
A thorough review of supernormal conduction.pptxA thorough review of supernormal conduction.pptx
A thorough review of supernormal conduction.pptx
 
Introducing VarSeq Dx as a Medical Device in the European Union
Introducing VarSeq Dx as a Medical Device in the European UnionIntroducing VarSeq Dx as a Medical Device in the European Union
Introducing VarSeq Dx as a Medical Device in the European Union
 
Book Trailer: PGMEE in a Nutshell (CEE MD/MS PG Entrance Examination)
Book Trailer: PGMEE in a Nutshell (CEE MD/MS PG Entrance Examination)Book Trailer: PGMEE in a Nutshell (CEE MD/MS PG Entrance Examination)
Book Trailer: PGMEE in a Nutshell (CEE MD/MS PG Entrance Examination)
 
NCLEX RN REVIEW EXAM CONTENT BLUE BOOK PDF
NCLEX RN REVIEW EXAM CONTENT BLUE BOOK PDFNCLEX RN REVIEW EXAM CONTENT BLUE BOOK PDF
NCLEX RN REVIEW EXAM CONTENT BLUE BOOK PDF
 
Factors Affecting child behavior in Pediatric Dentistry
Factors Affecting child behavior in Pediatric DentistryFactors Affecting child behavior in Pediatric Dentistry
Factors Affecting child behavior in Pediatric Dentistry
 
Video capsule endoscopy (VCE ) in children
Video capsule endoscopy (VCE ) in childrenVideo capsule endoscopy (VCE ) in children
Video capsule endoscopy (VCE ) in children
 
CT scan of penetrating abdominopelvic trauma
CT scan of penetrating abdominopelvic traumaCT scan of penetrating abdominopelvic trauma
CT scan of penetrating abdominopelvic trauma
 
Antiplatelets in IHD, Dose Duration, DAPT vs SAPT
Antiplatelets in IHD, Dose Duration, DAPT vs SAPTAntiplatelets in IHD, Dose Duration, DAPT vs SAPT
Antiplatelets in IHD, Dose Duration, DAPT vs SAPT
 
Cas 28578-16-7 PMK ethyl glycidate ( new PMK powder) best suppler
Cas 28578-16-7 PMK ethyl glycidate ( new PMK powder) best supplerCas 28578-16-7 PMK ethyl glycidate ( new PMK powder) best suppler
Cas 28578-16-7 PMK ethyl glycidate ( new PMK powder) best suppler
 
MRI Artifacts and Their Remedies/Corrections.pptx
MRI Artifacts and Their Remedies/Corrections.pptxMRI Artifacts and Their Remedies/Corrections.pptx
MRI Artifacts and Their Remedies/Corrections.pptx
 
Why invest into infodemic management in health emergencies
Why invest into infodemic management in health emergenciesWhy invest into infodemic management in health emergencies
Why invest into infodemic management in health emergencies
 
รายการตํารับยาแผนไทยแห่งชาติ ฉบับ พ.ศ. 2564.pdf
รายการตํารับยาแผนไทยแห่งชาติ ฉบับ พ.ศ. 2564.pdfรายการตํารับยาแผนไทยแห่งชาติ ฉบับ พ.ศ. 2564.pdf
รายการตํารับยาแผนไทยแห่งชาติ ฉบับ พ.ศ. 2564.pdf
 
The Orbit & its contents by Dr. Rabia I. Gandapore.pptx
The Orbit & its contents by Dr. Rabia I. Gandapore.pptxThe Orbit & its contents by Dr. Rabia I. Gandapore.pptx
The Orbit & its contents by Dr. Rabia I. Gandapore.pptx
 
DECIPHERING COMMON ECG FINDINGS IN ED.pptx
DECIPHERING COMMON ECG FINDINGS IN ED.pptxDECIPHERING COMMON ECG FINDINGS IN ED.pptx
DECIPHERING COMMON ECG FINDINGS IN ED.pptx
 
Muscle Energy Technique (MET) with variant and techniques.
Muscle Energy Technique (MET) with variant and techniques.Muscle Energy Technique (MET) with variant and techniques.
Muscle Energy Technique (MET) with variant and techniques.
 
Cervical screening – taking care of your health flipchart (Vietnamese)
Cervical screening – taking care of your health flipchart (Vietnamese)Cervical screening – taking care of your health flipchart (Vietnamese)
Cervical screening – taking care of your health flipchart (Vietnamese)
 

QPS Biomarkers & Translational Medicine

  • 1. TIME IS OF THE ESSENCE IN DRUG DEVELOPMENT. CONTACT THE QPS BUSINESS DEVELOPMENT TEAM TODAY! CALL +1 512 350 2827 EMAIL infobd@qps.com Biomarkers & Translational Medicine A flexible approach to AT QPS, TRANSLATIONAL MEDICINE BRINGS TOGETHER LEADING-EDGE TECHNOLOGIES AND pharmaceutical research and development experience to create a business service unit that works efficiently to advance your drug development program.
  • 2. Fargo, ND, USA Dermal and Transdermal Research Laboratory (DTRL) Groningen and Leeuwarden, The Netherlands Bioanalysis (BA) Clinical Research Services (CRS) Translational Medicine (TLM) Suzhou and Shanghai, China Bioanalysis (BA) Clinical Research Services (CRS) Miami, FL, USA Clinical Research Services (CRS) Hyderabad, India Bioanalysis (BA) Clinical Research Services (CRS) Taipei, Taiwan Bioanalysis (BA) Clinical Research Services (CRS) Toxicology (TOX) Newark, DE, USA Bioanalysis (BA) Clinical Research Services (CRS) DMPK Translational Medicine (TLM) Global Headquarters for QPS Holdings LLC Graz, Austria Clinical Research Services (CRS) DMPK Histology Services Neuropharmacology Rare Disease Rodent Biobank Springfield, MO, USA Clinical Research Services (CRS) Translational Medicine Overview Projects in translational medicine include qualification/ validation of commercially available kits, method transfer of assays originated from the Sponsor’s lab, or a collaborative effort between the QPS team and the Sponsor’s lab for custom assays. We also develop assays independently without help from the Sponsor. In addition to immunoassays for PK and immunogenicity assessment, QPS develops cell-based assays for neutralizing antibody activity and biomarker evaluation in support of your drug development programs. Validation & Qualification We work diligently with clients to determine best practices for conducting biomarker or other pharmacodynamic studies to support both preclinical studies and clinical trials. As pharmacodynamics assays are often for explorative use only, we have adopted a “fit- for purpose” to qualify and validate assays. QPS can plan a “fit-for-purpose” method qualification or validation that identifies the key tests needed to ensure the suitability of an assay method on an individual basis. We can provide a shorter method qualification, usually performed with a vendor-qualified assay kit. A qualification typically includes 3 or more precision and accuracy runs and matrix testing. In this case, assay specifications including more extensive validation tests are provided by the assay vendor. As a “fit-for-purpose” qualification, additional tests may be added based on the nature of the assay and specific study considerations. In some cases, an inter-laboratory cross validation may be performed for data comparison, using 20-30 samples provided by the sponsor. In a “fit-for-purpose” method validation, the individual biomarker characteristics and the study specifics are used to determine which of these tests are appropriate. Some tests may be eliminated on an individual basis if they are not applicable to the particular biomarker, not useful for a specific type of assay (e.g. activity assay) or if they are not relevant to the clinical or pre-clinical study our method is supporting. Additional tests may be added given the same considerations. A full method validation is typically described in a sponsor- approved validation protocol and includes at least six assay runs to determine both inter- and intra-batch precision and accuracy, dilution linearity (hook effect tests), matrix selectivity, matrix effect (n ≥ 6) and necessary stability tests including benchtop (ambient temperature), freeze-thaw and long-term storage. QPS is a Global CRO with locations around the world WWW.QPS.COM